Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Blood (2023) 141 (19): 2359–2371.

https://doi.org/10.1182/blood.2022018244

Published: 2023

Includes: Supplemental data

Journal Articles

Attenuation of Graft-Versus-Host-Disease Via Genetic or Pharmacologic Inhibition of the RNA Splicing Factor RBM39

Jessie Bourcier, Simon J. Hogg, Caroline Erickson, Michael E Singer, Steven Tittley, Takahiro Ito, Anastasiya Egorova, Jason Kuttiyara, Alan M. Hanash, Omar Abdel-Wahab, Sydney X. Lu

Blood (2022) 140 (Supplement 1): 1163–1164.

https://doi.org/10.1182/blood-2022-156727

Published: 2022

Journal Articles

A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes

Jan Philipp Bewersdorf, Maximilian F. Stahl, Justin Taylor, Namrata Sonia Chandhok, Justin Watts, Andriy Derkach, Mateusz Wysocki, Victoria Kostantakis, Sydney X. Lu, Jessie Bourcier, Simon Hogg, Tulasigeri M Totiger, Omar Abdel-Wahab, Eytan Stein

Blood (2022) 140 (Supplement 1): 9065–9067.

https://doi.org/10.1182/blood-2022-156830

Published: 2022

Journal Articles

Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

Blood (2022) 140 (Supplement 1): 2088–2090.

https://doi.org/10.1182/blood-2022-158992

Published: 2022

Journal Articles

Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures

Blood (2021) 138 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2021-150684

Published: 2021

Journal Articles

A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study

Urvi A Shah, Daniel Alicea, Peter A. Adintori, Miranda Burge, Jenna Blaslov, Andriy Derkach, Sham Mailankody, Neha Korde, Carlyn Tan, Malin Hultcrantz, Sydney X. Lu, Dhwani Patel, Hani Hassoun, Anita D'Souza, Sergio A Giralt, Neil Iyengar, Ola Landgren, Marcel van den Brink, Alexander Lesokhin

Blood (2021) 138 (Supplement 1): 4759.

https://doi.org/10.1182/blood-2021-151049

Published: 2021

Journal Articles

The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations

Blood (2021) 138 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2021-148095

Published: 2021

Journal Articles

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Blood (2021) 138 (Supplement 1): 3271.

https://doi.org/10.1182/blood-2021-145927

Published: 2021

Journal Articles

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience

Blood (2021) 138 (Supplement 1): 1644.

https://doi.org/10.1182/blood-2021-153443

Published: 2021

Journal Articles

VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup

Carlyn Tan, MD, Benjamin Diamond, MD, Malin Hultcrantz, MD PhD, Neha Korde, MD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Hani Hassoun, MD, Urvi A Shah, MD, Sydney X. Lu, MD PhD, Dhwani Patel, MD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Andriy Derkach, PhD, Sergio A. Giralt, MD, Ola Landgren, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-141988

Published: 2020

Journal Articles

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

Ola Landgren, MD PhD, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Hani Hassoun, MD, Carlyn Tan, MD, Urvi A Shah, MD, Sydney X. Lu, MD PhD, Benjamin Diamond, MD, Meghan Salcedo, RN, Kelly Werner, RN, Jenna Rispoli, RN, Julia Caple, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Isabel Concepcion, NP, Ciardello Amanda, MS, Aisara Chansakul, BS, Julia Schlossman, BA, Elizabet Tavitian, BS, Tala Shekarkhand, BS, Angela Harrison, MS, Casey Piacentini, BS, Even H Rustad, MD PhD, Venkata Yellapantula, PhD, Francesco Maura, MD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Katie Thoren, Kazunori Murata, PhD, Lakshmi Ramanathan, PhD, Maria E. Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Andriy Derkach, PhD, Sergio A. Giralt, MD, Neha Korde, MD

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-142466

Published: 2020

Journal Articles

A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-141131

Published: 2020

Journal Articles

ZRSR2 Mutation Induced Minor Intron Retention Drives MDS and Diverse Cancer Predisposition Via Aberrant Splicing of LZTR1

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136445

Published: 2020

Journal Articles

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Benjamin Diamond, MD, Neha Korde, MD, Alexander M. Lesokhin, MD, Eric L Smith, MDPhD, Urvi A Shah, MD, Sham Mailankody, MBBS, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Sydney X. Lu, MD PhD, Carlyn Tan, MD, Donna Massey, MSN, RN, Meghan Salcedo, BSN, RN, Victoria Diab, RN, Kelly Werner, RN, Jenna Rispoli, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Julia Schlossman, BA, Aisara Chansakul, BS, Angela Harrison, MS, Amanda Kathryn Ciardiello, Elizabet Tavitian, BS, Tala Shekarkhand, BS, Casey Piacentini, BS, Even H Rustad, MD PhD, Venkata D Yellapantula, Francesco Maura, MD, Tim J Peterson, PharmD, Andriy Derkach, PhD, Sean Devlin, PhD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan L. Shah, MDMS, Oscar B Lahoud, MD, Katie Thoren, Kazunori Murata, Lakshmi Ramanathan, PhD, Maria E. Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Sergio A. Giralt, MD, Ola Landgren, MD PhD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-140152

Published: 2020

Journal Articles

Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-142082

Published: 2020

Journal Articles

Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias

Daichi Inoue, MD PhD, Chew Guo-Liang, Bo Liu, PhD, Stanley C Lee, PhD, Brittany C Michel, Joey Pangallo, B.S., Andrew R D'Avino, Khrystyna North, Lillian E Bitner, BSc, Muran Xiao, Susumu Kobayashi, Akihide Yoshimi, MD PhD, Hana Cho, MSc, Sydney X Lu, MD PhD, Justin Taylor, MD, Cigall Kadoch, PhD, Robert K. Bradley, PhD, Omar Abdel-Wahab, MD

Blood (2019) 134 (Supplement_1): 637.

https://doi.org/10.1182/blood-2019-124616

Published: 2019

Journal Articles

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

Katrina M Piedra, PharmD, Hani Hassoun, MD, Larry W. Buie, PharmD, BCOP, FASHP, Sean M. Devlin, PhD, Jessica Flynn, BS, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sydney X Lu, MD PhD, Sham Mailankody, MBBS, Urvi A Shah, MD, Eric L Smith, MD PhD, Ola Landgren, MD PhD, Neha Korde, MD, Tim J Peterson, PharmD

Blood (2019) 134 (Supplement_1): 1835.

https://doi.org/10.1182/blood-2019-124403

Published: 2019

Journal Articles

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

Blood (2019) 134 (Supplement_1): 862.

https://doi.org/10.1182/blood-2019-126378

Published: 2019

Journal Articles

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

Marion Eveillard, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Eric L Smith, MD PhD, Hani Hassoun, MD, Urvi A Shah, MD, Sydney X Lu, MD PhD, Neha Korde, MD, Ola Landgren, MD PhD, Katie Thoren, PhD

Blood (2019) 134 (Supplement_1): 4377.

https://doi.org/10.1182/blood-2019-128938

Published: 2019

Journal Articles

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Ola Landgren, MD PhD, Donna Mastey, RN, Alexander M. Lesokhin, MD, Eric L Smith, MD PhD, Urvi A Shah, MD, Sham Mailankody, MBBS, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Sydney X Lu, MD PhD, Meghan Salcedo, RN, Victoria Diab, RN, Kelly Werner, RN, Jenna Rispoli, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Julia Schlossman, BA, Aisara Chansakul, BS, Angela Harrison, MS, Amanda Ciardiello, BS, Elizabeth Tavitian, BS, Tala Shekarkhand, BS, Even Rustad, MD, Venkata Yellapantula, PhD, Francesco Maura, MD, Tim J Peterson, PharmD, Sean M. Devlin, PhD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Katie Thoren, PhD, Kazunori Murata, PhD, Lakshmi Ramanathan, PhD, Maria E Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Sergio Giralt, MD, Neha Korde, MD

Blood (2019) 134 (Supplement_1): 3127.

https://doi.org/10.1182/blood-2019-125842

Published: 2019

NARROW

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Attenuation of Graft-Versus-Host-Disease Via Genetic or Pharmacologic Inhibition of the RNA Splicing Factor RBM39

A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes

Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures

A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study

The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)

ZRSR2 Mutation Induced Minor Intron Retention Drives MDS and Diverse Cancer Predisposition Via Aberrant Splicing of LZTR1

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients

Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only